| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7389935 | Value in Health Regional Issues | 2017 | 9 Pages |
Abstract
The present study concludes that the SOF + DCV regimen among other currently available regimens is the most cost-saving option that yields the most favorable future health economic outcomes compared with the SOF + pegIFN + RBV regimen across a broad spectrum of patients, including those with cirrhosis.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Gihan Hamdy MSc, PhD, Asmaa BSc, Emam MD,